Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Neoplasms 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Urinary Bladder Neoplasms 1Sarcoma 1Prostatic Neoplasms 1NSCLC 1Lymphoma, Non-Hodgkin 1Lymphedema 1Leukemia, Myeloid, Chronic-Phase 1Gynecological Cancers 1Fibrosis 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal, Breast 1Breast Neoplasms 1BRAF V600 Colorectal Cancer 1Anxiety Disorders 1Adenomatous Polyposis Coli 1

Interventions

Paclitaxel 56Carboplatin 56Bevacizumab 43Gemcitabine 20Taxes 19pembrolizumab 15Immunoglobulin G 13Disulfides 13Topotecan 12olaparib 11Cisplatin 11niraparib 9Cyclophosphamide 9liposomal doxorubicin 8Specimen Handling 7Docetaxel 6Biopsy 6mirvetuximab soravtansine 5Nivolumab 5Magnetic Resonance Spectroscopy 5Letrozole 5Hyperthermic Intraperitoneal Chemotherapy 5Drug Therapy 5Cytoreduction Surgical Procedures 5Albumin-Bound Paclitaxel 5rucaparib 4pazopanib 4oregovomab 4Surgical Procedures, Operative 4Neoadjuvant Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Neoplasms × Pharmaceutical Preparations × Clear all
NCT06690775 2025-12-23

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

TORL Biotherapeutics, LLC

Phase 2 Recruiting
230 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡